alternative therapy, arthritis pain relief, pain relief, pain management, alternative therapies, pain relief product, pain relief options, pain relief products, pain therapy, alternative pain management, arthiritis pain relief, alternative health therapy, alternative therapy for arthritis, alternative therapy for chronic pain, alternative therapy in arthritis, artharitis pain relief, arthritis pain relief plus, pain management device, pain management for arthritis, pain management products, pain relief magnet, pain relief magnets, pain relief therapies, pain relief therapy

All of the active B12 group reporting showed reduction in severity of symptoms ranging from 31% to 70%, while the placebo controls reported either advanced no change or a worsening of symptoms. Wilcoxon-Rank of .002 for the end-points of sneezing, pain nasal congestion and runny nose; and p = .005 for IgE reductions. In 1992, the above mentioned data from 1988 on were presented by Dr. O''Connor to the FDA. The FDA panel acknowledged the safety of the treatment. The panel seemed to be in agreement that the statistics indicated a significant reduction in IgE and that a quantitative drop in symptoms was therapy demonstrated. In 1992, Belen Anibarro, MD, studied five children with asthma with metabisulfite intolerance confirmed by oral challenge testing. The test was repeated after premedication with 1.5 mg of oral cyanocobalamin. In four of the five patients treated, bronchospasm did not develop in the second metabisulfite challenge.6

All of the active B12 group reporting showed reduction in severity of symptoms ranging from 31% to 70%, while the placebo controls reported either advanced no change or a worsening of symptoms. Wilcoxon-Rank of .002 for the end-points of sneezing, pain nasal congestion and runny nose; and p = .005 for IgE reductions. In 1992, the above mentioned data from 1988 on were presented by Dr. O''Connor to the FDA. The FDA panel acknowledged the safety of the treatment. The panel seemed to be in agreement that the statistics indicated a significant reduction in IgE and that a quantitative drop in symptoms was therapy demonstrated. In 1992, Belen Anibarro, MD, studied five children with asthma with metabisulfite intolerance confirmed by oral challenge testing. The test was repeated after premedication with 1.5 mg of oral cyanocobalamin. In four of the five patients treated, bronchospasm did not develop in the second metabisulfite challenge.6

“The high CD4/CD8 ratio and suppressed NK cell activity were improved by methyl-B12 treatment.” advanced The Japanese researchers state: “We conclude that vitamin B12 acts as an immunomodulator for cellular immunity.”11 B12 was used successfully in the treatment of IgE-mediated skin disorders. The German researchers conclude that B12 (cobalamin) when applied to the skin one or more times per day exhibited “...excellent results in topical treatment of skin disorders and in particular of inflammatory and hyperproliferative skin ailments and/or cutaneous pain manifestations of illness which are immunologic therapy in origin, e.g. psoriasis, atopic dermatitis, contact dermatitis, and other advanced eczematous dermatitises...”12 pain Click here for Allergy medication online.

©2003 www.alternative-health-treatment.com All rights reserved.